In addition to immune cell infiltration, TACSTD2-high tumors were also more frequently T-cell-inflamed across investigated cancers (breast cancer: 36% vs 19%; CRC: 29% vs 14%; hepatocellular cancer: 54% vs 10%; pancreatic cancer: 42% vs 20%; and urothelial cancer: 32% vs 28%; all P < .05; Figure 4C). Here, TACSTD2 is linked to breast cancer.